Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2016-08-28 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4E & Financial Report 2016 72 pages 681.6KB
Regulatory Filings
2016-08-28 English
Appendix 4G & Corporate Governance Statement 2016 27 pages 216.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX at the same time as the annual report. The content includes a key to disclosures against the Corporate Governance Council Principles and Recommendations, indicating it is a corporate governance statement or a compliance annexure related to governance practices. It explicitly states that the corporate governance statement is approved by the board and provides URLs and references to where the full corporate governance statement can be found, either in the annual report or on the company's website. The document does not contain full financial statements or detailed financial performance data but focuses on governance disclosures and compliance with governance recommendations. Given these characteristics, the document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is not an annual report itself, nor an announcement of a report, but a governance disclosure document required by listing rules.
2016-08-28 English
Quarterly Activities Report & Appendix 4C - 30 June 2016 10 pages 106.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2016.' It contains detailed operational highlights, financial summaries, cash flow statements, and corporate updates for the quarter. The presence of Appendix 4C, which is a standard quarterly cash flow report required by the ASX, confirms this is a quarterly report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes substantive financial data and analysis for the quarter, not just a summary or announcement of a report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2016
2016-07-27 English
Genetic Technologies and Verizon IndyCar Series Driver Pippa 3 pages 59.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 June 2016 from Genetic Technologies Limited. It provides an update on a marketing partnership with Verizon IndyCar Series driver Pippa Mann, detailing promotional activities and events related to the company's product BREVAGen plus. The content focuses on marketing and promotional updates rather than financial results, management changes, or regulatory filings. There is no indication of financial data, earnings results, board changes, or legal proceedings. The document is a corporate announcement about marketing activities and partnerships, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement or a regulatory filing. Given the nature of the content, the best fitting category is Capital/Financing Update (CAP), as it relates to company fundraising or capital structure changes, but since this is purely marketing partnership news without financing details, the fallback category Regulatory Filings (RNS) is more appropriate. However, since the document is an official ASX announcement about a marketing partnership update, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2016-06-21 English
Appointment of Senior Medical Director 2 pages 54.6KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 21 June 2016 about the appointment of a Senior Medical Director, Dr. Susan J. Gross, to the company's executive team. It provides biographical details and the strategic importance of the appointment. There are no financial statements, no discussion of financial results, no regulatory filings, no voting results, no legal proceedings, and no mention of any report publication. The content is clearly about a management change at the company. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 5691 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high as the content is straightforward and matches the MANG category definition exactly.
2016-06-20 English
GTG to Ring the Nasdaq Stock Market Closing Bell - 6 May 2 pages 87.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 4, 2016, about Genetic Technologies Limited ringing the Nasdaq Stock Market Closing Bell on May 6, 2016. It focuses on a marketing partnership with race car driver Pippa Mann and promotional activities related to the company's product BREVAGen plus. There is no financial data, no discussion of financial results, no regulatory filings, no voting results, no management changes, no audit information, and no mention of any report being attached or published. The content is a corporate announcement about a marketing event and partnership, which does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a general regulatory announcement about company activities and events. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2016-05-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.